ViaLase Receives CE Mark for First Femtosecond Laser for the Treatment of Glaucoma, the ViaLase® Laser USA - English USA - English USA - español
The Californer/10286965

~ ViaLase, Inc., a clinical-stage medical technology company, has recently received CE Mark approval in the European Union (EU) for its innovative ViaLase® Laser. This laser is designed to address unmet needs in the conventional glaucoma treatment paradigm and provide a non-invasive option for adult patients with primary open-angle glaucoma (POAG).

The ViaLase Laser combines the precision of a femtosecond laser with micron-level image guidance to deliver a procedure called femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT). This technology aims to offer patients a non-pharmacologic and incision-free alternative to traditional surgical procedures while still achieving their therapeutic goals.

According to Tibor Juhasz, PhD, Founder and Chief Executive Officer of ViaLase, Inc., the approval of the ViaLase Laser marks a significant advancement in interventional glaucoma care. He believes that this technology has the potential to deliver surgery-like results without the need for invasive procedures that can lead to complications. Early clinical data also suggests that FLigHT is safe and effective at lowering intraocular pressure (IOP).

More on The Californer

• Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
• Author Calls Trump the Most Racist President in US History
• DERMA-CODE™ Announces Ingredient Transparency and Molecular Innovation in Skincare
• Michelle L Crocker releases a new book called Do Not Date An Asshole
• Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood

Richard Lewis, MD, Chief Medical Officer of ViaLase, Inc., also expressed his excitement about the approval of the ViaLase Laser. He believes that early intervention with non-medical treatments can offer better long-term disease control and preserve vision for patients. The advanced imaging and precision offered by this laser will bring a new level of care to glaucoma patients.

ViaLase plans to roll out the ViaLase Laser selectively in key markets later this year. The company has established partnerships with Global Surgical Service in Spain and Portugal and Teleon Surgical in Germany and Austria. These distributors have extensive experience in ophthalmology and established commercial presence in their respective markets. This strategic collaboration will ensure a timely and efficient introduction of the ViaLase Laser to physicians and patients.

It is important to note that the ViaLase Laser is not yet approved for use in the United States. However, with its CE Mark approval in the EU, it is expected to bring significant advancements in glaucoma treatment and improve the lives of patients worldwide.

---

Show All News | Report Violation